↓ Read PDF
01 · ABSTRACT

Abstract

In the space of two years, three adeno-associated virus (AAV) gene therapy treatments were licensed for the treatment of haemophilia. By mid 2026, however, two had been withdrawn, leaving a single product available whose uptake has not matched that which was envisaged. This commentary suggests that this failure of uptake is due to a mismatch between regulatory approval, the cost of the treatment, and the real-world value of the treatment to the haemophilia community. Drawing on these threads, this paper examines other haematological conditions for which gene therapies have been developed (Sickle Cell Disease (SCD)) and are in development (Glanzmann Thrombasthenia (GT) and von Willebrand disease (vWD)) and proposes that the lessons of haemophilia gene therapy; embedding patient experience early, pre-specifying meaningful outcomes, its position against improving standards of care and confronting economics and equity from the outset.
↓ Read PDF
02 · OJS METADATA

Keywords

HaemophiliaSickle Cell DiseaseGene therapyQualitative Research
03 · PUBLICATION RECORD

Article details

JournalMedical Research Archives
IssueVol 14 No 10 (2026): Vol.14 Issue 10 October 2026
SectionReview Articles
Published31 October 2026
DOI10.18103/mra.2026.0632
ISSN2375-1924
04 · RIGHTS & REUSE

Rights & reuse

This article is published under a Creative Commons Attribution License (CC BY 4.0) and may be shared or distributed by anyone as long as attribution is given to the journal.

Authors & affiliations

Medical Research Archives

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Start your submission  ↗